Inicio / De Interés / Notigalderma / MAL-PDT OR PLACEBO CREAM IN NODULAR BASAL CELL CARCINOMA

MAL-PDT OR PLACEBO CREAM IN NODULAR BASAL CELL CARCINOMA

RESULTS OF AN AUSTRALIAN DOUBLE BLIND RANDOMIZED MULTICENTER STUDY

INTRODUCTION:

Basal Cell Carcinoma (BCC) is a highly frequent skin malignancy, and accounts for approximately 75% of all non-melanoma skin cancers, affecting mostly the head and neck in fair-skinned individuals. Simple surgical excision is currently regarded as the treatment of choice; however cosmetic outcome is often less than optimal.

Photodynamic therapy (PDT) is a treatment modality, involving the activation of a photosensitizing agent by light, leading to the formation of reactive oxygen species. This process results in local tissue destruction and may therefore offer an attractive alternative to surgery.

Application of methylaminolevulinate (MAL) leads to the selective formation of photoactive porphyrins in tumor cells. Previous clinical experience has been promising and patients with nodular Basal Cell Carcinoma (nBCC) were recruited for participation in this multicenter, randomized trial to assess the efficacy, safety and cosmetic outcome of MAL-PDT (1-5). 

Descargue artículo completo aquí: mal-pdt-or-placebo-cream-in-bccn.pdf

Acerca de Laboratorios Galderma

Deja un comentario

Para casos clínicos, sólo se publicarán comentarios de Suscriptores Especialistas de Salud registrados en nuestra base de datos.

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

 

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies